DOSSIER · UPDATED 18 NOV 2025

OrsoBio

OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring…

orsobio.com ↗Claim this profile

Founded: 2021
Headcount: 14
Open roles: 0
Last raised: Series B · $67M

SECTION I · THE BRIEF

Inside OrsoBio

Brief #19705Updated 18 NOV 2025PALO ALTOSOFTWARE COMPANIESSERIES B

Employbl Dossier

OrsoBio

Founded: 2021
Headcount: 14
Open roles: 0
Last raised: Series B · $67M

Section II · Premium ProfileMembers only

01Engineering interview process at OrsoBioLocked
02Tech stack & infrastructure choicesLocked
03Culture & day-to-day work styleLocked
04Why join now vs. 6 months from nowLocked
05Hiring focus & open headcount by teamLocked
06Comp philosophy and band contextLocked

Open OrsoBio brief Sign in

7-day free trial · $25/mo · cancel anytime

LEADERSHIP

Founders & key people

Gans Ganapati

G. Mani Subramanian

Muzammil Mansuri

OPEN ROLES

Hiring at OrsoBio

No open roles listed right now. Check back soon or search all jobs →

FUNDING

Capital raised

Total Amount Raised: $129,300,000

OrsoBio Funding Rounds

Series B
$67,000,000
Sep 6, 2024
Series B
$67,000,000
Sep 5, 2024
Series B Investors
Ascenta Capital
Woodline Partners
Longitude Capital
Samsara BioCapital
Enavate Sciences
NuevaBio
Eli Lilly and Company
Series A
$60,000,000
Nov 7, 2023
Series A
$60,000,000
Nov 6, 2023
Series A Investors
Enavate Sciences
Longitude Capital
NuevaBio
Samsara BioCapital
Eli Lilly and Company
Grant
$2,300,000
Nov 2, 2022
Grant
$2,300,000
Nov 1, 2022
Grant Investors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)